EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Empiric dosing strategies to predict lamotrigine concentrations during pregnancy

Jessica M Barry iD, Jacqueline A French iD, Page B Pennell iD, Ashwin Karanam, Cynthia L Harden, Angela K Birnbaum iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023

DOI: 10.1002/phar.2856 ↗

At a glance

Journal article in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023. Written by Jessica M Barry and 5 co-authors. Institution: Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA. Major MEDLINE topics: Epilepsy, Pregnancy Complications. Cited 5 times so far (Crossref); 16 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NICHD NIH HHS, Epilepsy Foundation, Eunice Kennedy Shriver National Institute of Child Health and Human Development.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

Maintaining seizure control with lamotrigine is complicated by altered pharmacokinetics and existence of subpopulations in whom clearance increases or remains constant during pregnancy.

Objective

Our objective was to characterize the potential for particular dosing scenarios to lead to increased seizure risk or toxicity.

Methods

Lamotrigine pharmacokinetic parameters obtained from our previous study were applied to a one‐compartment model structure with subpopulations (75:25%) exhibiting different clearance changes. A single‐patient simulation was conducted with typical pharmacokinetic parameter values from each subpopulation. Population‐level simulations ( N = 48,000) included six dosing scenarios and considered four preconception doses using the R package mrgsolve (Metrum Research Group). Thresholds for efficacy and toxicity were selected as drug concentration that are 65% lower than preconception concentrations and doubling of preconception concentrations, respectively.

Results

Individual simulation results demonstrated that without dose increases, concentrations fell below 0.65 at 6–8 weeks in the high clearance change (HC) subpopulation, depending on preconception clearance. While no simulated dosing regimen allowed all women in both subpopulations to maintain preconception concentrations, some regimens provided a more balanced risk profile than others. Predicted concentrations suggested potential increased seizure risk for 7%–100% of women in the HC group depending on preconception dose and subpopulation. Additionally, in 63% of dosing scenarios for women with low clearance change (LC), there was an increased risk of toxicity (34%–100% of women). Significance A substantial percentage of simulated individuals had concentrations low enough to potentially increase seizure risk or high enough to create toxicity. Early clearance changes indicate possible subpopulation categorization if therapeutic drug monitoring is conducted in the first trimester. An arbitrary “one‐size‐fits‐all” philosophy may not work well for lamotrigine dosing adjustments during pregnancy and reinforces the need for therapeutic drug monitoring until a patient is determined to be in the LC or HC group.

Subjects

MeSH terms (MEDLINE)

EpilepsyPregnancy ComplicationsPregnancyFemaleHumansLamotrigineAnticonvulsantsSeizures

Author keywords

drug monitoringepilepsylamotriginepregnancysimulation

Substances

LamotrigineAnticonvulsants

Authors and institutions

  • Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Neurology, New York University Comprehensive Epilepsy Center, New York City, New York, USA.
  • University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Xenon Pharmaceuticals, Inc., Burnaby, British Columbia, Canada.

ORCID profiles: Jessica M Barry, Jacqueline A French, Page B Pennell, Angela K Birnbaum

Funding

  • NICHD NIH HHS
  • Epilepsy Foundation
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • University of Minnesota

Cite

APA

Barry, J. M., French, J. A., Pennell, P. B., Karanam, A., Harden, C. L., & Birnbaum, A. K. (2023). Empiric dosing strategies to predict lamotrigine concentrations during pregnancy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2856

Vancouver

Barry JM, French JA, Pennell PB, Karanam A, Harden CL, Birnbaum AK. Empiric dosing strategies to predict lamotrigine concentrations during pregnancy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023. doi:10.1002/phar.2856

BibTeX
@article{Barry2023,
  author = {Barry, Jessica M and French, Jacqueline A and Pennell, Page B and Karanam, Ashwin and Harden, Cynthia L and Birnbaum, Angela K},
  title = {Empiric dosing strategies to predict lamotrigine concentrations during pregnancy},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2023},
  doi = {10.1002/phar.2856}
}
Start for free →